You are not logged in.

Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study

Bousman, Chad A., Müller, Daniel J., Ng, Chee H., Byron, Keith, Berk, Michael and Singh, Ajeet B. 2017, Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study, Pharmacogenetics and genomics, vol. 27, no. 1, pp. 1-6, doi: 10.1097/FPC.0000000000000253.

Attached Files
Name Description MIMEType Size Downloads

Title Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study
Author(s) Bousman, Chad A.
Müller, Daniel J.
Ng, Chee H.
Byron, Keith
Berk, MichaelORCID iD for Berk, Michael orcid.org/0000-0002-5554-6946
Singh, Ajeet B.
Journal name Pharmacogenetics and genomics
Volume number 27
Issue number 1
Start page 1
End page 6
Total pages 6
Publisher Wolters Kluwer Health
Place of publication London, Eng.
Publication date 2017-01
ISSN 1744-6872
1744-6880
Summary Background Pharmacogenetic-based dosing support tools have been developed to personalize antidepressant-prescribing practice. However, the clinical validity of these tools has not been adequately tested, particularly for specific antidepressants.

Objective To examine the concordance between the actual dose and a polygene pharmacogenetic predicted dose of desvenlafaxine needed to achieve symptom remission.

Materials and methods A 10-week, open-label, prospective trial of desvenlafaxine among Caucasian adults with major depressive disorder (n=119) was conducted. Dose was clinically adjusted and at the completion of the trial, the clinical dose needed to achieve remission was compared with the predicted dose needed to achieve remission.

Results Among remitters (n=95), there was a strong concordance (Kendall's τ-b=0.84, P=0.0001; Cohen's κ=0.82, P=0.0001) between the actual and the predicted dose need to achieve symptom remission, showing high sensitivity (≥85%), specificity (≥86%), and accuracy (≥89%) of the tool. Conclusion Findings provide initial evidence for the clinical validity of a polygene pharmacogenetic-based tool for desvenlafaxine dosing.
Language eng
DOI 10.1097/FPC.0000000000000253
Field of Research 110319 Psychiatry (incl Psychotherapy)
0604 Genetics
1115 Pharmacology And Pharmaceutical Sciences
Socio Economic Objective 920410 Mental Health
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2016, Wolters Kluwer Health
Persistent URL http://hdl.handle.net/10536/DRO/DU:30090265

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 53 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Fri, 16 Dec 2016, 11:21:21 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.